ASX - By Stock
|
CHM |
Re:
Ann: 1st patient treated in ADVENT-AML Phase 1b clinical trial
|
|
raz0r11
|
39 |
14K |
2 |
25/03/24 |
25/03/24 |
ASX - By Stock
|
39
|
14K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Ann: 1st patient treated in ADVENT-AML Phase 1b clinical trial
|
|
raz0r11
|
39 |
14K |
0 |
12/03/24 |
12/03/24 |
ASX - By Stock
|
39
|
14K
|
0
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Chimeric to present at ********* Hidden Gems webinar
|
|
raz0r11
|
17 |
5.2K |
3 |
01/03/24 |
01/03/24 |
ASX - By Stock
|
17
|
5.2K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Half Yearly Report and Accounts
|
|
raz0r11
|
17 |
4.4K |
0 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
17
|
4.4K
|
0
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Half Yearly Report and Accounts
|
|
raz0r11
|
17 |
4.4K |
1 |
29/02/24 |
29/02/24 |
ASX - By Stock
|
17
|
4.4K
|
1
|
|
ASX - By Stock
|
CHM |
Re:
biotech could be sector for 2024
|
|
raz0r11
|
10 |
4.1K |
5 |
02/02/24 |
02/02/24 |
ASX - By Stock
|
10
|
4.1K
|
5
|
|
ASX - By Stock
|
CHM |
Re:
Ann: ADVENT-AML Phase 1B clinical trial open to enrolment
|
|
raz0r11
|
24 |
7.0K |
5 |
21/01/24 |
21/01/24 |
ASX - By Stock
|
24
|
7.0K
|
5
|
|
ASX - By Stock
|
CHM |
Re:
Ann: ADVENT-AML Phase 1B clinical trial open to enrolment
|
|
raz0r11
|
24 |
7.0K |
1 |
19/01/24 |
19/01/24 |
ASX - By Stock
|
24
|
7.0K
|
1
|
|
ASX - By Stock
|
CHM |
Re:
Ann: ADVENT-AML Phase 1B clinical trial open to enrolment
|
|
raz0r11
|
24 |
7.0K |
2 |
19/01/24 |
19/01/24 |
ASX - By Stock
|
24
|
7.0K
|
2
|
|
ASX - By Stock
|
CHM |
Re:
Ann: CHIMERIC RECEIVES $7.36M R&D TAX INCENTIVE
|
|
raz0r11
|
22 |
8.0K |
12 |
10/01/24 |
10/01/24 |
ASX - By Stock
|
22
|
8.0K
|
12
|
|
ASX - By Stock
|
CHM |
Re:
Ann: CHIMERIC RECEIVES $7.36M R&D TAX INCENTIVE
|
|
raz0r11
|
22 |
8.0K |
9 |
10/01/24 |
10/01/24 |
ASX - By Stock
|
22
|
8.0K
|
9
|
|
ASX - By Stock
|
CHM |
Re:
Ann: CHM Secures Further $1M Investment
|
|
raz0r11
|
15 |
5.6K |
6 |
04/01/24 |
04/01/24 |
ASX - By Stock
|
15
|
5.6K
|
6
|
|
ASX - By Stock
|
CHM |
Re:
Ann: FDA clearance of IND for CHM 2101
|
|
raz0r11
|
70 |
19K |
5 |
03/01/24 |
03/01/24 |
ASX - By Stock
|
70
|
19K
|
5
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Entitlement Offer closing date extended to 30 November 2023
|
|
raz0r11
|
29 |
9.1K |
1 |
27/11/23 |
27/11/23 |
ASX - By Stock
|
29
|
9.1K
|
1
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Entitlement Offer closing date extended to 30 November 2023
|
|
raz0r11
|
29 |
9.1K |
1 |
27/11/23 |
27/11/23 |
ASX - By Stock
|
29
|
9.1K
|
1
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Positive in vitro data for CHM 1301 CAR NK cells
|
|
raz0r11
|
79 |
19K |
4 |
23/11/23 |
23/11/23 |
ASX - By Stock
|
79
|
19K
|
4
|
|
ASX - By Stock
|
AL3 |
Re:
Ann: AML3D Wins Largest ARCEMY System Contract to Austal USA
|
|
raz0r11
|
8 |
2.3K |
0 |
20/11/23 |
20/11/23 |
ASX - By Stock
|
8
|
2.3K
|
0
|
|
ASX - By Stock
|
NGS |
Re:
Ann: Trading Halt
|
|
raz0r11
|
2 |
665 |
0 |
08/05/23 |
08/05/23 |
ASX - By Stock
|
2
|
665
|
0
|
|
ASX - By Stock
|
KCN |
Re:
Ann: Kingsgate completes $46M institutional placement
|
|
raz0r11
|
298 |
98K |
1 |
28/03/23 |
28/03/23 |
ASX - By Stock
|
298
|
98K
|
1
|
|
ASX - By Stock
|
KCN |
Re:
Ann: Kingsgate Equity Raising Presentation
|
|
raz0r11
|
49 |
18K |
0 |
27/03/23 |
27/03/23 |
ASX - By Stock
|
49
|
18K
|
0
|
|
ASX - By Stock
|
KCN |
Re:
Ann: Kingsgate Equity Raising Presentation
|
|
raz0r11
|
49 |
18K |
0 |
27/03/23 |
27/03/23 |
ASX - By Stock
|
49
|
18K
|
0
|
|
ASX - By Stock
|
CCX |
Re:
Ann: Trading Update for the 26 weeks to 1 January 2023
|
|
raz0r11
|
43 |
14K |
0 |
20/01/23 |
20/01/23 |
ASX - By Stock
|
43
|
14K
|
0
|
|
ASX - By Stock
|
CCX |
Re:
Ann: Trading Update & 1HFY23 Outlook
|
|
raz0r11
|
62 |
25K |
0 |
21/12/22 |
21/12/22 |
ASX - By Stock
|
62
|
25K
|
0
|
|
ASX - By Stock
|
CCX |
Re:
Ann: Trading Update & 1HFY23 Outlook
|
|
raz0r11
|
62 |
25K |
1 |
20/12/22 |
20/12/22 |
ASX - By Stock
|
62
|
25K
|
1
|
|
ASX - By Stock
|
CCX |
Re:
Ann: Trading Update & 1HFY23 Outlook
|
|
raz0r11
|
62 |
25K |
3 |
20/12/22 |
20/12/22 |
ASX - By Stock
|
62
|
25K
|
3
|
|
ASX - By Stock
|
CCX |
Re:
Ann: AGM Chair and CEO Address
|
|
raz0r11
|
71 |
25K |
1 |
28/11/22 |
28/11/22 |
ASX - By Stock
|
71
|
25K
|
1
|
|
ASX - By Stock
|
CCX |
Re:
Reputational damage done
|
|
raz0r11
|
26 |
10K |
2 |
26/11/22 |
26/11/22 |
ASX - By Stock
|
26
|
10K
|
2
|
|
ASX - By Stock
|
CCX |
Re:
Reputational damage done
|
|
raz0r11
|
26 |
10K |
2 |
25/11/22 |
25/11/22 |
ASX - By Stock
|
26
|
10K
|
2
|
|
ASX - By Stock
|
CCX |
Re:
Ann: City Chic Collective 2022 Annual General Meeting
|
|
raz0r11
|
21 |
8.5K |
2 |
25/11/22 |
25/11/22 |
ASX - By Stock
|
21
|
8.5K
|
2
|
|
ASX - By Stock
|
CCX |
Re:
Ann: FY22 Full year results presentation
|
|
raz0r11
|
30 |
13K |
0 |
02/09/22 |
02/09/22 |
ASX - By Stock
|
30
|
13K
|
0
|
|
ASX - By Stock
|
CHM |
Re:
valuation thoughts
|
|
raz0r11
|
380 |
174K |
0 |
03/05/22 |
03/05/22 |
ASX - By Stock
|
380
|
174K
|
0
|
|
ASX - By Stock
|
CCX |
Re:
Where to from here?
|
|
raz0r11
|
79 |
30K |
0 |
19/04/22 |
19/04/22 |
ASX - By Stock
|
79
|
30K
|
0
|
|
ASX - By Stock
|
CCX |
Re:
City Chic Cosmetics; it’s time!
|
|
raz0r11
|
8 |
2.2K |
0 |
19/04/22 |
19/04/22 |
ASX - By Stock
|
8
|
2.2K
|
0
|
|
ASX - By Stock
|
CHM |
Re:
valuation thoughts
|
|
raz0r11
|
380 |
174K |
0 |
18/04/22 |
18/04/22 |
ASX - By Stock
|
380
|
174K
|
0
|
|
ASX - By Stock
|
BGT |
Re:
Ann: Bio-Gene Executes Commercial Development Agreement
|
|
raz0r11
|
70 |
19K |
0 |
04/04/22 |
04/04/22 |
ASX - By Stock
|
70
|
19K
|
0
|
|
ASX - By Stock
|
BGT |
Re:
Ann: Strategic Placement of $1.5 million to Cornerstone Investor
|
|
raz0r11
|
107 |
26K |
4 |
15/03/22 |
15/03/22 |
ASX - By Stock
|
107
|
26K
|
4
|
|
ASX - By Stock
|
BGT |
Re:
Ann: Strategic Placement of $1.5 million to Cornerstone Investor
|
|
raz0r11
|
107 |
26K |
0 |
15/03/22 |
15/03/22 |
ASX - By Stock
|
107
|
26K
|
0
|
|
ASX - By Stock
|
CCX |
Re:
Evans: when is it starting to sell into Ireland?
|
|
raz0r11
|
1 |
611 |
0 |
14/03/22 |
14/03/22 |
ASX - By Stock
|
1
|
611
|
0
|
|
ASX - By Stock
|
CCX |
Re:
Ann: FY22 Interim Results Announcement
|
|
raz0r11
|
47 |
16K |
0 |
24/02/22 |
24/02/22 |
ASX - By Stock
|
47
|
16K
|
0
|
|
ASX - By Stock
|
CHM |
Re:
Instos
|
|
raz0r11
|
4 |
1.0K |
0 |
23/02/22 |
23/02/22 |
ASX - By Stock
|
4
|
1.0K
|
0
|
|
ASX - By Stock
|
CHM |
Instos
|
|
raz0r11
|
4 |
1.0K |
3 |
23/02/22 |
23/02/22 |
ASX - By Stock
|
4
|
1.0K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Successful completion of Institutional Entitlement Offer
|
|
raz0r11
|
10 |
3.5K |
0 |
23/02/22 |
23/02/22 |
ASX - By Stock
|
10
|
3.5K
|
0
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Trading Halt
|
|
raz0r11
|
32 |
9.6K |
4 |
21/02/22 |
21/02/22 |
ASX - By Stock
|
32
|
9.6K
|
4
|
|
ASX - By Stock
|
KCN |
Re:
Ann: Thailand Update
|
|
raz0r11
|
106 |
41K |
6 |
11/02/22 |
11/02/22 |
ASX - By Stock
|
106
|
41K
|
6
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Chimeric receives US patent covering CLTX CAR technology
|
|
raz0r11
|
21 |
7.9K |
1 |
02/02/22 |
02/02/22 |
ASX - By Stock
|
21
|
7.9K
|
1
|
|
ASX - By Stock
|
CCX |
Re:
Torrid
|
|
raz0r11
|
13 |
4.3K |
0 |
10/01/22 |
10/01/22 |
ASX - By Stock
|
13
|
4.3K
|
0
|
|
ASX - By Stock
|
CCX |
Re:
Ann: Becoming a substantial holder
|
|
raz0r11
|
10 |
2.9K |
0 |
13/09/21 |
13/09/21 |
ASX - By Stock
|
10
|
2.9K
|
0
|
|
ASX - By Stock
|
AL3 |
Re:
Ann: Breakthrough Welding Wire Composition Project
|
|
raz0r11
|
14 |
5.0K |
0 |
07/09/21 |
07/09/21 |
ASX - By Stock
|
14
|
5.0K
|
0
|
|
ASX - By Stock
|
GLN |
Re:
Charting
|
|
raz0r11
|
2.4K |
791K |
2 |
20/04/21 |
20/04/21 |
ASX - By Stock
|
2.4K
|
791K
|
2
|
|
ASX - By Stock
|
GLN |
Re:
Compelling opportunity
|
|
raz0r11
|
5.9K |
1.7M |
1 |
20/04/21 |
20/04/21 |
ASX - By Stock
|
5.9K
|
1.7M
|
1
|
|